Blue Sky Biotech infused with Ampersand VC backing
Blue Sky Biotech Inc., a Worcester-based contract research organization for the pharmaceutical industry, has taken an investment from private equity firm Ampersand Ventures of Wellesley. The amount of the investment was not disclosed.
As part of the financing deal, Ampersand General Partner Peter Glick will join the Blue Sky Biotech board of directors and serve as chairman. He previously was president of pharmaceutical firm Primedica, acquired by Charles River Laboratories International Inc. in 2001.